Matrix Metalloproteinases as a Therapeutic Target to Improve Neurologic Recovery After Spinal Cord Injury
Abstract
We are evaluating efficacy of GM6001, a matrix metalloproteinase (MMP) inhibitor in a murine model of spinal cord injury (UCSF) and in dogs (Texas A & M, TAMU) that sustain naturally occurring spinal cord injuries resulting from spontaneous intervertebral disk herniation (IVDH). Scope: These studies focus on efficacy of GM6001 in the context of an optimal therapeutic window and dependency on injury severity, using clinically relevant neurologic and urologic outcome measures.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA624276
Entities
People
- Aida F. Martinez
- Alpa Mahuvakar
- Jon Levine
- Linda J. Noble
- Thomas Fandel
Organizations
- University of California, San Francisco